Phosphagenics to expand manufacturing capabilities

28 May 2006

Phosphagenics, an Australia and London, UK, Stock Exchange listed company, says that it has commenced the construction of a production plant in Melbourne. The new unit will add to the firm's ability to manufacture tocopheryl phosphate, a component of many of its pharmaceutical and nutraceutical products and will provide capacity to meet anticipated future supply requirements. Due to be completed by the end of this year, the new facility will have an annual capacity of 100 tonnes of tocopheryl phosphates, with an estimated wholesale value of A$25.0 million ($18.5 million).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight